Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Period	Debt/Equity
2018-12-31	0.19
2019-12-31	-1.05
2020-12-31	-1.74
2021-12-31	-0.10
2022-12-31	-0.07
2023-12-31	1.20
2024-12-31	1.87

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TLSA	$1.29	+2.38%	0.14M
3
4
5

Tiziana Life Sciences Ltd (TLSA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Tiziana Life Sciences Ltd Data in Excel

More TLSA Financial Data